Invitrogen

Phospho-c-Met (Tyr1003) Polyclonal Antibody

Advanced Verification

This Antibody was verified by Cell treatment to ensure that the antibody binds to the antigen stated.

13 Published Figures

13 References

View all (88) c-Met antibodies

Datasheet

Protocols

Questions & Answers

Tech Support

Datasheet

Protocols

Questions & Answers

Tech Support

Phospho-c-Met (Tyr1003) Antibody in Immunohistochemistry (Paraffin) (IHC (P))

FIGURE: 1 / 18

Phospho-c-Met (Tyr1003) Antibody (44-882G) in IHC (P)

Immunohistochemistry analysis of Phospho-c-Met (pY1003) showing staining in the cytoplasm and membrane of paraffin-embedded mouse liver tissue (right) compared to a negative control without primary antibody (left). To expose target proteins, antigen retrieval was performed using 10mM sodium citrate (pH 6.0), microwaved for 8-15 min. Following antigen retrieval, tissues were blocked in 3% H2O2-methanol for 1... View More

Phospho-c-Met (Tyr1003) Antibody in Western Blot (WB)

Phospho-c-Met (Tyr1003) Antibody in Western Blot, Immunohistochemistry (Paraffin) (WB, IHC (P))

Phospho-c-Met (Tyr1003) Antibody in Immunohistochemistry (IHC)

Product Image Gallery

Product Details

44-882G

Applications

Tested Dilution

Publications

Western Blot (WB)

1:1,000

View 7 publications 7 publications

Immunohistochemistry (IHC)

View 4 publications 4 publications

Immunohistochemistry (Paraffin) (IHC (P))

1:20-1:200

View 1 publication 1 publication

Miscellaneous PubMed (Misc)

View 1 publication 1 publication

Product Specifications

Species Reactivity

Human, Mouse

Published species

Dog, Hamster, Human, Mouse

Host/Isotype

Rabbit / IgG

Class

Polyclonal

Type

Antibody

Immunogen

The antiserum was produced against a chemically synthesized phosphopeptide derived from the region of human c-Met that contains tyrosine 1003. The sequence is conserved in mouse and rat.

View immunogen

Conjugate

Unconjugated Unconjugated Unconjugated

Form

Liquid

Purification

Antigen affinity chromatography

Storage buffer

Dulbecco's PBS, pH 7.3, with 1mg/mL BSA

Contains

0.05% sodium azide

Storage conditions

-20°C

Shipping conditions

Ambient (domestic); Wet ice (international)

RRID

AB_2533786

Target Information

MET (cMET) is a receptor-like tyrosine kinase whose dysregulation has been linked to many types of human malignancies. After activation of the ligand, MET interacts with the PI3-kinase subunit PIK3R1, PLCG1, SRC, GRB2, and STAT3. There interactions lead to the activation of signaling cascades including RAS-ERK, PI3, kinase-AKT, and PLCgamma-PKC. MET plays a role in embryonic development including gastrulation, development of muscles and neurons, angiogenesis, and kidney formation. It also plays a role in adults including wound healing, organ regeneration, and tissue remodeling. MET has been linked to cancers including gastric, renal, and breast; therefore, making it a target for cancer therapeutics and diagnostic testing.

For Research Use Only. Not for use in diagnostic procedures. Not for resale without express authorization.

Product References

Suppressive impact of metronomic chemotherapy using UFT and/or cyclophosphamide on mediators of breast cancer dissemination and invasion.

PloS one

Muñoz R,Hileeto D,Cruz-Muñoz W,Wood GA,Xu P,Man S,Viloria-Petit A,Kerbel RS

Published figure using Phospho-c-Met (Tyr1003) polyclonal antibody (Product # 44-882G) in Immunohistochemistry

Fri Mar 06 00:00:00 EST 2020

Hypoxia-Driven Mechanism of Vemurafenib Resistance in Melanoma.

Molecular cancer therapeutics

Qin Y,Roszik J,Chattopadhyay C,Hashimoto Y,Liu C,Cooper ZA,Wargo JA,Hwu P,Ekmekcioglu S,Grimm EA

44882G was used in immunohistochemistry - paraffin section and western blot to find that upregulation of HGF/MET signaling is associated with vemurafenib resistance

Sat Oct 01 00:00:00 EDT 2016

Hypoxia-Driven Mechanism of Vemurafenib Resistance in Melanoma.

Molecular cancer therapeutics

Qin Y,Roszik J,Chattopadhyay C,Hashimoto Y,Liu C,Cooper ZA,Wargo JA,Hwu P,Ekmekcioglu S,Grimm EA

44882G was used in immunohistochemistry - paraffin section and western blot to find that upregulation of HGF/MET signaling is associated with vemurafenib resistance

Sat Oct 01 00:00:00 EDT 2016

Targeting c-Met in melanoma: mechanism of resistance and efficacy of novel combinatorial inhibitor therapy.

Cancer biology & therapy

Etnyre D,Stone AL,Fong JT,Jacobs RJ,Uppada SB,Botting GM,Rajanna S,Moravec DN,Shambannagari MR,Crees Z,Girard J,Bertram C,Puri N

44-882G was used in immunohistochemistry to investigate the role of mTOR and Wnt signaling proteins to c-Met TKI resistance in melanoma cell lines

Mon Sep 01 00:00:00 EDT 2014

Targeting c-Met in melanoma: mechanism of resistance and efficacy of novel combinatorial inhibitor therapy.

Cancer biology & therapy

Etnyre D,Stone AL,Fong JT,Jacobs RJ,Uppada SB,Botting GM,Rajanna S,Moravec DN,Shambannagari MR,Crees Z,Girard J,Bertram C,Puri N

44-882G was used in immunohistochemistry to investigate the role of mTOR and Wnt signaling proteins to c-Met TKI resistance in melanoma cell lines

Mon Sep 01 00:00:00 EDT 2014

Anti-c-MET Nanobody - a new potential drug in multiple myeloma treatment.

European journal of haematology

Slørdahl TS,Denayer T,Moen SH,Standal T,Børset M,Ververken C,Rø TB

44-882G was used in western blot to examine the anticancer effect of a novel anti-c-MET Nanobody in multiple myeloma.

Fri Nov 01 00:00:00 EDT 2013

Expression of hepatocyte epidermal growth factor receptor, FAS and glypican 3 in EpCAM-positive regenerative clusters of hepatocytes, cholangiocytes, and progenitor cells in human liver failure.

Human pathology

Hattoum A,Rubin E,Orr A,Michalopoulos GK

44-882G was used in immunohistochemistry to study regenerative clusters in the liver histologically.

Wed May 01 00:00:00 EDT 2013

Alternative signaling pathways as potential therapeutic targets for overcoming EGFR and c-Met inhibitor resistance in non-small cell lung cancer.

PloS one

Fong JT,Jacobs RJ,Moravec DN,Uppada SB,Botting GM,Nlend M,Puri N

44-882G was used in western blot to study the molecular mechanisms underlying development of resistance to tyrosine kinase inhibitors in non-small cell lung cancer.

Fri Aug 08 00:00:00 EDT 2014

MET and phosphorylated MET as potential biomarkers in lung cancer.

Journal of environmental pathology, toxicology and oncology : official organ of the International Society for Environmental Toxicology and Cancer

Tretiakova M,Salama AK,Karrison T,Ferguson MK,Husain AN,Vokes EE,Salgia R

44-882G was used in immunohistochemistry to assess expression and prognostic role of the receptor tyrosine kinase MET, phosphorylated MET, and the ligand hepatocyte growth factor in patients with lung cancer.

Thu Feb 16 00:00:00 EST 2012

The MET receptor tyrosine kinase is a potential novel therapeutic target for head and neck squamous cell carcinoma.

Cancer research

Seiwert TY,Jagadeeswaran R,Faoro L,Janamanchi V,Nallasura V,El Dinali M,Yala S,Kanteti R,Cohen EE,Lingen MW,Martin L,Krishnaswamy S,Klein-Szanto A,Christensen JG,Vokes EE,Salgia R

44-882G was used in western blot to study MET receptor tyrosine kinase as a potential novel therapeutic target for head and neck squamous cell carcinoma

Wed Apr 01 00:00:00 EDT 2009

The MET receptor tyrosine kinase is a potential novel therapeutic target for head and neck squamous cell carcinoma.

Cancer research

Seiwert TY,Jagadeeswaran R,Faoro L,Janamanchi V,Nallasura V,El Dinali M,Yala S,Kanteti R,Cohen EE,Lingen MW,Martin L,Krishnaswamy S,Klein-Szanto A,Christensen JG,Vokes EE,Salgia R

44-882G was used in western blot to study MET receptor tyrosine kinase as a potential novel therapeutic target for head and neck squamous cell carcinoma

Wed Apr 01 00:00:00 EDT 2009

Functional expression and mutations of c-Met and its therapeutic inhibition with SU11274 and small interfering RNA in non-small cell lung cancer.

Cancer research

Ma PC,Jagadeeswaran R,Jagadeesh S,Tretiakova MS,Nallasura V,Fox EA,Hansen M,Schaefer E,Naoki K,Lader A,Richards W,Sugarbaker D,Husain AN,Christensen JG,Salgia R

Tue Feb 15 00:00:00 EST 2005

A selective small molecule inhibitor of c-Met kinase inhibits c-Met-dependent phenotypes in vitro and exhibits cytoreductive antitumor activity in vivo.

Cancer research

Christensen JG,Schreck R,Burrows J,Kuruganti P,Chan E,Le P,Chen J,Wang X,Ruslim L,Blake R,Lipson KE,Ramphal J,Do S,Cui JJ,Cherrington JM,Mendel DB

Sat Nov 01 00:00:00 EST 2003

A selective small molecule inhibitor of c-Met kinase inhibits c-Met-dependent phenotypes in vitro and exhibits cytoreductive antitumor activity in vivo.

Cancer research

Christensen JG,Schreck R,Burrows J,Kuruganti P,Chan E,Le P,Chen J,Wang X,Ruslim L,Blake R,Lipson KE,Ramphal J,Do S,Cui JJ,Cherrington JM,Mendel DB

Sat Nov 01 00:00:00 EST 2003

A selective small molecule inhibitor of c-Met kinase inhibits c-Met-dependent phenotypes in vitro and exhibits cytoreductive antitumor activity in vivo.

Cancer research

Christensen JG,Schreck R,Burrows J,Kuruganti P,Chan E,Le P,Chen J,Wang X,Ruslim L,Blake R,Lipson KE,Ramphal J,Do S,Cui JJ,Cherrington JM,Mendel DB

Sat Nov 01 00:00:00 EST 2003

Bioinformatics

Protein Aliases: cMet; EC 2.7.10.1; Hepatocyte growth factor receptor; HGF receptor; HGF-SF receptor; HGF/SF receptor; met proto-oncogene tyrosine kinase; oncogene MET; Proto-oncogene c-Met; sc MET; Scatter factor receptor; SF receptor; soluble c met; Tyrosine-protein kinase Met

View more View less

Gene Aliases: AI838057; AUTS9; c-Met; DFNB97; HGF; HGFR; MET; Par4; RCCP2

View more View less

UniProt ID: (Human) P08581

View more View less

Entrez Gene ID: (Human) 4233, (Mouse) 17295

View more View less

Function(s)

protein tyrosine kinase activity hepatocyte growth factor-activated receptor activity protein binding ATP binding protein phosphatase binding nucleotide binding protein kinase activity transmembrane receptor protein tyrosine kinase activity beta-catenin binding kinase activity transferase activity transferase activity, transferring phosphorus-containing groups protein complex binding phospholipase binding phosphatidylinositol 3-kinase binding protein heterodimerization activity transmembrane signal receptor

Process(es)

Performance Guarantee

If an Invitrogen™ antibody doesn't perform as described on our website or datasheet,we'll replace the product at no cost to you, or provide you with a credit for a future purchase.*

Learn more

Phospho-c-Met (Tyr1003) Polyclonal Antibody

Phospho-c-Met (Tyr1003) Antibody (44-882G) in IHC (P)

Product Details

44-882G

Western Blot (WB)

Immunohistochemistry (IHC)

Immunohistochemistry (Paraffin) (IHC (P))

Miscellaneous PubMed (Misc)

Species Reactivity

Published species

Host/Isotype

Class

Type

Immunogen

Conjugate

Form

Purification

Storage buffer

Contains

Storage conditions

Shipping conditions

RRID

Target Information

Bioinformatics

Performance Guarantee

We're here to help

Your items have has been added!